MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
BioCardia, Inc. (NASDAQ: BCDA)*
Organization & Developments: BioCardia
Parents
BioCardia, Inc. (NASDAQ: BCDA)*
Children
*Development-stage company focused on cellular and cell-derived therapies for cardiovascular and pulmonary diseases, alongside enabling delivery technologies for targeted biologic administration to the heart.
2020: BioCardia Fills in a Key Piece of CardiaAmp Puzzle with New Clearance
2022: BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
2022: Trial of CardiAMP (BCDA-02) to treat chronic myocardial ischemia is a cell therapy that utilizes bone marrow cells injected into the heart.
Jumps
Finance & Acquisitions: BioCardia
Key People: BioCardia